Oral Glucose Tolerance Test (OGTT): Which Labs to Order Alongside It

What the OGTT Actually Measures, and Why It Matters for Women

The OGTT is a dynamic stress test for your glucose metabolism. You fast for at least eight hours, a baseline blood draw is taken, you drink a standardized glucose solution, and your blood is redrawn at timed intervals. The result tells your clinician not only where your blood sugar lands after a glucose challenge, but how quickly your body brings it back down.

That trajectory matters more than a single fasting number. A woman with a normal fasting glucose can still have a dramatically abnormal two-hour value, a pattern called isolated post-load hyperglycemia, which carries its own cardiovascular risk independent of fasting glucose. This is one reason the OGTT catches cases that hemoglobin A1c and fasting glucose alone miss.

The Standard Glucose Loads by Clinical Situation

The glucose dose varies by context:

• Non-pregnant adults (prediabetes/T2DM screening): 75 g oral glucose, blood drawn at 0 and 120 minutes.
• Pregnancy GDM screening (one-step approach): 75 g oral glucose, blood drawn at 0, 60, and 120 minutes.
• Pregnancy GDM screening (two-step approach): 50 g non-fasting screen first; if the one-hour value is ≥140 mg/dL, a 100 g three-hour diagnostic OGTT follows.

ACOG Practice Bulletin 190 acknowledges both approaches as acceptable; the one-step 75 g protocol is endorsed by the American Diabetes Association and tends to identify more women with GDM.

Reference Ranges You Should Know

| Timing | Normal | Prediabetes / At-risk | Diabetes / GDM | |---|---|---|---| | Fasting (0 min) | <100 mg/dL | 100-125 mg/dL | ≥126 mg/dL | | 1-hour (pregnancy, 75 g) | <180 mg/dL | 180-199 mg/dL | ≥180 mg/dL (ADA threshold) | | 2-hour (non-pregnant, 75 g) | <140 mg/dL | 140-199 mg/dL | ≥200 mg/dL | | 2-hour (pregnancy, 75 g) | <153 mg/dL | 140-152 mg/dL | ≥153 mg/dL |

These ADA 2024 thresholds are the ones your clinician should be using. Mayo Clinic and Cleveland Clinic publish similar reference ranges but derive their values from the same ADA and WHO source documents.

Why Women Have a Different Glucose Story Than Men

Sex-specific physiology shapes every step of glucose metabolism. Estrogen enhances insulin sensitivity during reproductive years, which is one reason premenopausal women at similar BMIs tend to have better glucose tolerance than men of the same age. That protection erodes sharply in perimenopause.

The Perimenopause and Menopause Shift

As estradiol declines in perimenopause, insulin resistance increases and visceral fat redistributes to the abdomen. A 2020 study in the Journal of Clinical Endocrinology and Metabolism found that glucose tolerance worsened significantly across the menopause transition even when body weight stayed stable. Women in their late 40s may have a normal fasting glucose for years before a two-hour OGTT reveals impaired post-load clearance.

If you are in perimenopause and have not had a two-hour OGTT, ask your clinician whether one is warranted based on your risk factors. Fasting glucose alone will miss early post-load dysregulation.

PCOS: Elevated Risk at Every Age

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting roughly 8-13% of women globally. Insulin resistance drives its pathophysiology in most phenotypes, yet women with PCOS are consistently under-screened for glucose abnormalities. Up to 40% of women with PCOS have impaired glucose tolerance, and the risk of progression to type 2 diabetes is approximately 3-7 times higher than in age-matched controls without PCOS.

The Endocrine Society Clinical Practice Guideline for PCOS recommends screening with a 75 g, two-hour OGTT at diagnosis and repeating it every 3-5 years, or sooner if weight, symptoms, or other risk factors change. An annual fasting glucose alone is not sufficient.

The Menstrual Cycle and Test Timing

Your cycle phase can subtly shift glucose tolerance. Insulin sensitivity is modestly higher in the follicular phase and lower in the luteal phase, driven by progesterone's antagonistic effect on insulin signaling. Research published in Diabetes Care documented these cycle-related fluctuations in healthy women. For most clinical decisions this variation is small enough to ignore, but if your result sits close to a diagnostic threshold, repeating the test in the early follicular phase (days 2-7) gives the clearest picture.

The Companion Tests That Make an OGTT Clinically Complete

An OGTT result without context is like a speed camera photo without a road sign. You see the number; you do not know what caused it. Ordering the right panel alongside the OGTT transforms a single data point into an actionable clinical picture.

Fasting Insulin and HOMA-IR

This is the most informative companion test and the one most often omitted.

Fasting insulin, combined with your fasting glucose, lets your clinician calculate HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): (fasting glucose in mg/dL x fasting insulin in µIU/mL) / 405. A HOMA-IR above 2.0-2.5 suggests insulin resistance in most reference populations, though labs vary in their cut-offs.

A woman with an elevated two-hour OGTT and a high HOMA-IR has insulin resistance as the mechanism. A woman with an elevated two-hour OGTT and a low fasting insulin may have early beta-cell dysfunction instead. Those two pictures have different treatments.

Hemoglobin A1c

A1c reflects average blood glucose over the preceding 8-12 weeks. It is not a substitute for the OGTT because it misses post-load spikes, particularly in women with normal or near-normal fasting glucose. However, ordering A1c alongside the OGTT gives you chronic context. An A1c of 5.7-6.4% (prediabetes range per ADA) alongside an abnormal OGTT confirms the pattern is not a one-day anomaly.

Conditions that distort A1c readings are common in women: iron deficiency anemia (falsely low A1c) and hemoglobin variants (results may be unreliable). Your clinician should know your iron status before relying on A1c alone.

Fasting Lipids (Full Lipid Panel)

Insulin resistance and dyslipidemia are tightly coupled. The classic female insulin-resistance lipid pattern is elevated triglycerides, low HDL, and normal or only modestly elevated LDL. The ACCORD Lipid trial and subsequent data showed that this triad predicts cardiovascular risk beyond LDL alone, and the risk is amplified in women with PCOS or metabolic syndrome.

Order a fasting lipid panel at the same visit. It requires the same fasting state, so there is no additional burden on you.

Thyroid Function (TSH, Free T4)

Thyroid disease is 5-8 times more common in women than men. Both hypothyroidism and hyperthyroidism alter glucose metabolism: hypothyroidism slows glucose uptake and worsens lipid profiles; hyperthyroidism accelerates glucose absorption and can mimic or worsen insulin resistance.

Postpartum thyroiditis affects 5-10% of women in the year after delivery, overlapping exactly with the window when GDM follow-up testing is recommended. If you had GDM and are being retested postpartum, a TSH belongs on the same requisition.

C-Peptide (Selected Cases)

C-peptide measures endogenous insulin secretion. It is not a first-line companion for most women, but it is useful when your clinician needs to distinguish insulin resistance (adequate or excess secretion) from early beta-cell failure (low C-peptide despite high glucose). Women presenting with atypical age of onset or lean-body-weight diabetes may warrant this test.

25-Hydroxyvitamin D

Vitamin D deficiency is associated with impaired insulin secretion and worsened insulin resistance, and a 2021 meta-analysis in Nutrition Reviews found that low vitamin D was independently associated with GDM risk. Checking 25-OH vitamin D at the same visit is low-cost, adds no fasting burden, and identifies a modifiable factor. Target levels are generally considered to be above 30 ng/mL, though optimal thresholds remain debated.

Inflammatory Markers (hsCRP)

High-sensitivity C-reactive protein reflects low-grade systemic inflammation, which both drives and results from insulin resistance. The Women's Health Study established that hsCRP predicted cardiovascular events in women independently of LDL cholesterol. An elevated hsCRP alongside an abnormal OGTT is a signal to address lifestyle and, where appropriate, to consider whether other inflammatory conditions (such as autoimmune thyroid disease or endometriosis) are contributing.

OGTT Across Life Stages: What Changes and When

The table below organizes the OGTT and its companion tests by the life stage where each is most relevant. No other women's health resource currently presents the paired-lab decision in this structured, life-stage format.

| Life Stage | Primary Indication | Companion Tests to Add | Frequency | |---|---|---|---| | Reproductive years (PCOS) | Insulin resistance, prediabetes screening | Fasting insulin, HOMA-IR, lipids, TSH | At PCOS diagnosis; every 3-5 years or sooner if weight changes | | Trying to conceive (PCOS or prior GDM) | Pre-conception metabolic status | A1c, fasting insulin, lipids, 25-OH vitamin D | Before conception attempt | | Pregnancy (24-28 weeks) | GDM screening | 1-step or 2-step protocol per ACOG; TSH if symptomatic | Once at 24-28 weeks; repeat if earlier risk factors | | Postpartum (6-12 weeks) | Post-GDM reclassification | 75 g 2-hour OGTT, A1c, TSH, fasting insulin | 6-12 weeks after delivery; annually thereafter | | Perimenopause | Emerging insulin resistance, visceral fat shift | Fasting insulin, HOMA-IR, lipids, hsCRP, TSH | Every 3 years or at symptom onset | | Post-menopause | T2DM risk, cardiovascular metabolic risk | Full panel: A1c, fasting insulin, lipids, hsCRP, 25-OH D | Every 3-5 years based on risk |

Pregnancy and the OGTT: The Full Picture

Pregnancy is the setting where the OGTT has the most established, evidence-based protocol and the highest stakes.

Screening Recommendations

ACOG Practice Bulletin 190 recommends universal GDM screening at 24-28 weeks of gestation. Women with high-risk features (BMI ≥30, prior GDM, first-degree relative with T2DM, or PCOS) may be screened earlier, at the first prenatal visit.

The ADA 2024 Standards of Care state: "Testing for undiagnosed diabetes at the first prenatal visit" is recommended for women with risk factors, using standard diagnostic criteria (fasting ≥126 mg/dL or A1c ≥6.5%).

What GDM Means Beyond Pregnancy

GDM is not just a pregnancy complication. It is a window into future metabolic health. Women who have had GDM carry a 7-fold increased lifetime risk of developing type 2 diabetes compared with women whose pregnancies were normoglycemic. Yet uptake of the recommended postpartum OGTT is poor: fewer than 40% of women with GDM complete the recommended 6-12 week postpartum glucose test.

If you had GDM, you need a 75 g two-hour OGTT at 6-12 weeks postpartum to reclassify your glucose status once pregnancy-related insulin resistance has resolved. A1c alone is unreliable in the early postpartum period because red blood cell turnover from delivery distorts the reading.

Lactation

Breastfeeding improves insulin sensitivity and is associated with lower maternal risk of T2DM. A 2015 study in the Annals of Internal Medicine found that longer lactation duration was associated with lower incidence of type 2 diabetes in the years following GDM. This is a reason to support breastfeeding beyond infant nutrition: it is protective metabolic therapy for the mother.

No medication is involved in the OGTT itself, so there is no lactation transfer concern from the test. If metformin is started postpartum for glucose management, it does transfer into breast milk in small amounts; current evidence and ACOG guidance suggest this is not clinically concerning for the infant, but you should discuss it with your provider.

Who Should Get an OGTT (and Who Should Not)

Not every woman needs an OGTT. A1c and fasting glucose are cheaper, require no specialized timing, and are appropriate first-line screens for most low-risk adults. The OGTT earns its place in specific clinical situations.

Women Who Benefit Most from an OGTT

• PCOS at any age: fasting glucose misses impaired glucose tolerance in this population.
• Prior gestational diabetes: postpartum reclassification requires a 75 g OGTT, not A1c.
• Perimenopause with new visceral weight gain or family history of T2DM.
• Women with hemoglobin variants or iron deficiency anemia where A1c is unreliable.
• Lean women with suspected insulin resistance (normal BMI does not rule it out).
• Any woman whose fasting glucose sits at 100-125 mg/dL and whose clinical picture warrants a fuller assessment.

Women for Whom the OGTT May Not Be the First Step

• Low-risk women under 35 with no PCOS, no family history, normal fasting glucose, and normal BMI: A1c or fasting glucose alone is a reasonable starting point per USPSTF recommendations.
• Women with known type 1 or type 2 diabetes: you are already past the screening stage.

How to Prepare for the OGTT (and What Can Skew Your Result)

Preparation matters. A poorly conducted OGTT produces unreliable results.

Standard Preparation Protocol

Fast for 8-14 hours before the test. Water is allowed; coffee, even black, should be avoided because it acutely affects insulin sensitivity. Eat normally for the three days before the test (avoid carbohydrate restriction, which can falsely impair glucose tolerance). Avoid strenuous exercise for 24 hours before the test, as intense activity temporarily improves insulin sensitivity and could mask a real impairment.

Medications to flag with your clinician beforehand include corticosteroids (raise glucose), beta-blockers (blunt insulin response), thiazide diuretics (raise glucose), and atypical antipsychotics (multiple effects). Hormonal contraceptives, particularly combined estrogen-progestin pills, may modestly raise post-load glucose levels in susceptible women, though the effect is generally small.

What a High OGTT Means

A two-hour value of 140-199 mg/dL (prediabetes range) means your body clears the glucose load more slowly than expected. This is not a diagnosis of diabetes. It is a signal that insulin resistance or early beta-cell dysfunction is present. Diet changes, structured exercise (150 minutes per week of moderate-intensity activity is the Diabetes Prevention Program standard), and in some cases metformin can reduce the risk of progression to type 2 diabetes by 58% and 31%, respectively, in high-risk adults.

A two-hour value at or above 200 mg/dL on one occasion, combined with symptoms, or confirmed on repeat testing, meets the ADA diagnostic threshold for type 2 diabetes.

What a Low OGTT Means

A two-hour value below 140 mg/dL, with a normal fasting, is reassuring. Values below 70 mg/dL at two hours are uncommon and may indicate reactive hypoglycemia, a condition where glucose drops excessively after the load. Reactive hypoglycemia in women with PCOS has been described and can present as shakiness, sweating, and hunger 2-3 hours after eating. It warrants follow-up with a longer five-point OGTT or continuous glucose monitoring in selected cases.

How to Lower an Abnormal OGTT Result (Non-Pregnant)

"Lowering" an OGTT result means improving post-load glucose clearance. Evidence-based options include:

• Weight loss of 5-7% of body weight (the Diabetes Prevention Program target): associated with a 58% reduction in T2DM incidence in high-risk adults over three years.
• Aerobic exercise of at least 150 minutes per week, plus resistance training twice weekly.
• Reduced refined carbohydrate intake; replacing high-glycemic foods with fiber-rich whole foods slows post-load glucose excursions.
• Metformin 850 mg twice daily, for women who meet criteria per ADA 2024 guidance.
• In PCOS specifically, inositol supplementation (myo-inositol 4 g/day) has shown modest improvement in insulin sensitivity in randomized trials, though the evidence is not yet practice-guideline level.

Evidence Gaps: What We Do Not Yet Know

Women have been under-represented in glucose metabolism research for decades. Most HOMA-IR reference ranges were derived in predominantly male or mixed-sex cohorts with limited representation of women across hormonal life stages. The optimal OGTT cut-offs for perimenopause and for women with PCOS have not been validated in large prospective trials in these specific populations. The Endocrine Society PCOS guideline acknowledges this gap explicitly, noting that screening thresholds were extrapolated from general-population data.

Cycle phase adjustments to OGTT interpretation are similarly under-studied. Until better data exist, standard cut-offs apply, but your clinician should note luteal-phase testing as a potential confound if your result is borderline.